Reduction of Elimination of Mitral Regurgitation With the SATURN TMVR System (CASSINI-US)
NCT: NCT07130994 · NOT_YET_RECRUITING
Brief Summary
CASSINI-US is a prospective, single-arm, multicenter early feasibility study enrolling up to 15 patients at up to 5 sites in the United States (US). The purpose of the study is to evaluate the technical (implant) feasibility, and safety, and performance of the SATURN TS TMVR System for the treatment of moderate-severe or severe, symptomatic mitral regurgitation through a transcatheter approach. Primary objectives evaluate the implant feasibility, and acute safety and performance of the SATURN TS TMVR System. The secondary objective and additional outcome measures characterize the long-term safety and performance of the SATURN TS TMVR System.
Frequently Asked Questions
What is Reduction of Elimination of Mitral Regurgitation With the SATURN TMVR System (CASSINI-US)?
Reduction of Elimination of Mitral Regurgitation With the SATURN TMVR System (CASSINI-US) is a clinical trial registered under NCT07130994. Current status: NOT_YET_RECRUITING.
What is the status of NCT07130994?
The current status of NCT07130994 (Reduction of Elimination of Mitral Regurgitation With the SATURN TMVR System (CASSINI-US)) is: NOT_YET_RECRUITING.
When did Reduction of Elimination of Mitral Regurgitation With the SATURN TMVR System (CASSINI-US) start?
Reduction of Elimination of Mitral Regurgitation With the SATURN TMVR System (CASSINI-US) started on 2026-06.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.